SIC 8071 – Medical Laboratories
| Valuation | |
|---|---|
| Market Cap ($M) | 468.95 |
| Enterprise Value ($M) | 553.27 |
| Book Value ($M) | 149.71 |
| Book Value / Share | 4.03 |
| Price / Book | 3.13 |
| NCAV ($M) | 149.11 |
| NCAV / Share | 4.02 |
| Price / NCAV | 3.14 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.38 |
| Return on Assets (ROA) | -0.66 |
| Return on Equity (ROE) | -1.01 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 10.36 |
| Current Ratio | 10.36 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 272.44 |
| Assets | 273.04 |
| Liabilities | 123.33 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Ra Capital Management, L.p. | 3.40 | 0.00 | |
| 13G/A | Soleus Private Equity Fund II, L.P. | 9.90 | ||
| 13G/A | Venrock Healthcare Capital Partners III, L.P. | 0.00 | -100.00 | |
| 13G/A | Commodore Capital Lp | 5.90 | -11.03 | |
| 13G | Baker Bros. Advisors Lp | 5.10 | ||
| 13G/A | Morgan Stanley | 3.80 | -36.60 | |
| 13G | Biotechnology Value Fund L P | 9.90 | ||
| 13G/A | Perceptive Advisors Llc | 6.10 | 2.78 | |
| 13G/A | Soleus Capital Master Fund, L.P. | 9.90 | 14.80 | |
| 13G/A | Laing Lance G. | 5.50 | 3.44 | |
| 13G/A | Sullivan Brian F. | 14.00 | 4.84 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 28,768 | 107,419 | 26.78 | |
| 72,743 | 274,004 | 26.55 | |
| 42,762 | 113,999 | 37.51 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| BGLC – BioNexus Gene Lab Corp. | EXAS – Exact Sciences Corporation |
| MDXH – MDxHealth SA | PMD – Psychemedics Corporation |
| VRDN – Viridian Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io